- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Moderate to Severe Plaque Psoriasis in Singapore
Total 11 results
-
Novartis PharmaceuticalsCompletedModerate to Severe Plaque-type PsoriasisUnited States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-Type PsoriasisUnited States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
-
Novartis PharmaceuticalsCompletedModerate to Severe Plaque-type PsoriasisGermany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
-
NovartisCompletedModerate to Severe HypertensionRussian Federation, Romania, Singapore, Spain, Germany, Philippines
-
Singapore General HospitalTranslational Immunology InstituteRecruitingPlaque PsoriasisSingapore
-
Singapore General HospitalTranslational Immunology InstituteNot yet recruitingPlaque PsoriasisSingapore
-
Johnson & Johnson Pte LtdCompletedPlaque PsoriasisTaiwan, Korea, Republic of, Malaysia, Singapore, Indonesia
-
Singapore Eye Research InstituteUnknownFuchs' Endothelial Dystrophy | Bullous Keratopathy | Mild to Moderate Corneal Endothelial Decompensation | Post-surgical Corneal Decompensation (Irreversible)Singapore
-
Novartis PharmaceuticalsCompletedChronic Plaque PsoriasisGermany, United States, Colombia, Italy, Spain, Belgium, Egypt, Hungary, Australia, Singapore, France, Sweden, Guatemala, Philippines, Korea, Republic of, United Kingdom, Argentina, Poland, Romania, Canada, Iceland, India, Finland
-
Galderma R&DCompletedModerate-to-Severe Atopic DermatitisUnited States, Belgium, Bulgaria, Estonia, France, Georgia, Germany, Hungary, Italy, Poland, Singapore
-
Galderma R&DActive, not recruitingModerate-to-Severe Atopic DermatitisUnited States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, United Kingdom